Suzetrigine for Pain from Diabetic Nerve Damage

Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy

Recruiting Phase 3 Interventional Study
Diabetic Peripheral Neuropathic Pain
Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 80
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
1,100 (estimated)
Sponsor
Vertex Pharmaceuticals Incorporated · Industry
Who this trial is looking for

This trial is looking for people who have pain in their legs due to diabetic nerve damage. Participants will take a medication called Suzetrigine and help researchers understand how well it works and how safe it is.

Are You a Good Fit for This Trial?

You may be able to join if

  • I weigh at least 45 kilograms.
  • I have a BMI between 18.0 and 40.0.
  • I have been diagnosed with diabetes type 1 or type 2.
  • I have pain in both legs due to diabetic peripheral neuropathy.
  • My average pain score is between 4 and 9.

You may not be able to join if

  • I missed more than 3 daily pain score checks last week.
  • I have any other sensory problems besides diabetic neuropathy.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN).

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Key Inclusion Criteria: * Body weight greater than or equal to (≥) 45 kilogram (kg) * Body mass index (BMI) ≥18.0 to less than (\<) 40.0 kilogram per meter square (kg/m\^2) * Diagnosis of diabetes mellitus type 1 or type 2 by glycosylated hemoglobin A1c (HbA1c) ≤9% and the presence of bilateral pai…
Contacts

Medical Information

617-341-6777

medicalinfo@vrtx.com

CONTACT